Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director · CEO & President | September 08, 2026 | September 08, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | March 24, 2020 | March 26, 2020 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date September 08, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 357,507 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 5,658 · Balance 357,507 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 239,233 unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #1 | 18,000 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 18,000 F4: These shares are held in a trust for the benefit of a child of the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #2 | 18,000 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 18,000 F4: These shares are held in a trust for the benefit of a child of the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #3 | 18,000 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 18,000 F4: These shares are held in a trust for the benefit of a child of the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #4 | 18,000 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 18,000 F4: These shares are held in a trust for the benefit of a child of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Includes 239,233 unvested RSUs.
F4: These shares are held in a trust for the benefit of a child of the Reporting Person.
REPLIGEN CORP
Report date March 24, 2020 · Filed March 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 923 |
Reported balance
After 2020-03-24 transaction · row 1
1 source rowRow 1 · 2020-03-24 · Sale · Disposed 1,858 · Balance 923 |
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 341 · Balance 0 F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F3: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F3: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share
F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F3: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 1
1 source rowRow 1 · 2018-03-08 · Disposition to issuer · Disposed 185,094 · Balance 0 F1: Includes 67,780 shares subject to restricted stock units. See also note 4. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-08 · Disposition to issuer · Disposed 136,364 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-08 · Disposition to issuer · Disposed 48,678 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.82 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-08 · Disposition to issuer · Disposed 48,230 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-08 · Disposition to issuer · Disposed 387,366 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-08 · Disposition to issuer · Disposed 193,683 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 67,780 shares subject to restricted stock units. See also note 4.
F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.
F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 8, 2026 20:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,658 | $18.88 | $106,823.04 |
DisclosureSEC source: 0001498428-26-000005 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 357,507 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 239,233 unvested RSUs. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 20:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4,986 | $26.28 | $131,032.08 |
DisclosureSEC source: 0001498428-26-000004 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 363,165 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 248,314 unvested RSUs. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,683 | $18.33 | $49,179.39 |
DisclosureSEC source: 0001498428-26-000002 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 368,151 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 259,564 unvested RSUs. Read SEC document |
| May 13, 2026 Filed May 14, 2026 20:02 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 3,311 | $18.36 | $60,789.96 |
DisclosureSEC source: 0001193125-26-223955 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 370,834 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 268,645 unvested RSUs. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,732 | $14.90 | $40,706.80 |
DisclosureSEC source: 0001193125-26-096512 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374,145 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 279,895 unvested RSUs. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 285,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-055075 · ownership.xml · derivative · entry 6 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2036-02-11 F4 · derivative.exercise_date: This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-055075 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,877 F1 · shares: Consists of shares of Common Stock issuable under 180,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026. F2 · balance_after: Includes 288,976 unvested RSUs. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 21:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,662 | $20.72 | $55,156.64 |
DisclosureSEC source: 0001193125-25-309666 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,877 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · kind: The Reporting Person's sale of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the extent of 2,662 shares, with the Reporting Person's purchase of 100,000 shares on July 14, 2025. The Reporting Person has paid to the Issuer an aggregate amount of $31,111.88, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.58 to $20.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F4 · balance_after: Includes 108,976 unvested RSUs. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 20:31 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,640 | $13.41 | $35,402.40 |
DisclosureSEC source: 0001498428-25-000003 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,539 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · kind: The Reporting Person's sale of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the extent of 2,640 shares, with the Reporting Person's purchase of 100,000 shares on July 14, 2025. The Reporting Person has paid to the Issuer an aggregate amount of $11,565.07, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act. F3 · balance_after: Includes 118,057 unvested RSUs. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 21:19 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 197,285 | $0.00 Strike: $9.33 | $0.00 |
DisclosureSEC source: 0000950170-25-097005 · ownership.xml · derivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,285 Underlying: Common Stock · 197,285 shares Expires 2035-07-15 F1 · derivative.exercise_date: This option was granted on July 16, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest over three years, with 50% of the shares underlying the grant vesting 18 months after the Grant Date and with the balance of the shares underlying the grant vesting in equal quarterly installments thereafter; provided that such option shall not be exercisable unless and until (i) the average closing price of the common stock on the Nasdaq Global Select Market over a 20 consecutive trading day period equals or exceeds $20.00 per share at any time during the three-year period following the Grant Date (the "Performance Period") or (ii) a Change in Control (as defined in the Issuer's Amended and Restated Executive Severance and Change in Control Benefits Plan) is consummated during the Performance Period pursuant to which a third party acquires the common stock for a price per share that the Board of Directors of the Issuer determines equals or exceeds $20.00 per share. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095929 · ownership.xml · nonDerivative · entry 8 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,179 F3 · shares: This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person. F5 · balance_after: Includes 127,138 unvested RSUs. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095929 · ownership.xml · nonDerivative · entry 6 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,179 F3 · shares: This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095929 · ownership.xml · nonDerivative · entry 4 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,179 F3 · shares: This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095929 · ownership.xml · nonDerivative · entry 2 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,179 F3 · shares: This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person. Read SEC document |
| July 14, 2025 Filed Jul 15, 2025 21:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 100,000 | $9.11 | $911,000.00 |
DisclosureSEC source: 0000950170-25-095929 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,179 F1 · kind: The Reporting Person's purchase of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the extent of 8,121 shares, with the Reporting Person's sale of 4,061 shares on March 5, 2025 and 4,060 shares on June 5, 2025 automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The Reporting Person has paid to the Issuer an aggregate amount of $29,017.22, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $9.02 to $9.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4,060 | $13.35 | $54,201.00 |
DisclosureSEC source: 0000950170-25-083071 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,179 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.21 to $13.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 127,138 unvested RSUs. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4,061 | $11.83 | $48,041.63 |
DisclosureSEC source: 0000950170-25-035495 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,239 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.73 to $11.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 136,219 unvested RSUs. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 232,100 | $0.00 Strike: $29.44 | $0.00 |
DisclosureSEC source: 0000950170-24-134072 · ownership.xml · derivative · entry 6 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,100 Underlying: Common Stock · 232,100 shares Expires 2034-12-03 F4 · derivative.exercise_date: This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 145,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-134072 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,300 F1 · shares: Consists of shares of Common Stock issuable under 145,300 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025. F2 · balance_after: Includes 145,300 unvested RSUs. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 7,200 | $33.09 | $238,248.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 8 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #4 Disclosed balance after: 8,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 800 | $32.57 | $26,056.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 7 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #4 Disclosed balance after: 800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 7,200 | $33.09 | $238,248.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 6 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #3 Disclosed balance after: 8,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 800 | $32.57 | $26,056.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 5 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #3 Disclosed balance after: 800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 7,200 | $33.09 | $238,248.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 4 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #2 Disclosed balance after: 8,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 800 | $32.57 | $26,056.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 3 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #2 Disclosed balance after: 800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 7,200 | $33.09 | $238,248.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 2 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #1 Disclosed balance after: 8,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 800 | $32.57 | $26,056.00 |
DisclosureSEC source: 0000950170-24-103533 · ownership.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust #1 Disclosed balance after: 800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F2 · ownership.nature: These shares are held in a trust for the benefit of a child of the Reporting Person. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 20:24 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (Right to Buy) · Derivative | 679,853 | $0.00 Strike: $26.06 | $0.00 |
DisclosureSEC source: 0000950170-24-037226 · ownership.xml · derivative · entry 1 Cox John · CIK 0001498428 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,853 Underlying: Common Stock · 679,853 shares Expires 2034-03-24 F1 · derivative.exercise_date: This option was granted on March 25, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 25, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $5.00 Strike: $9.92 | $3,413.91 |
DisclosureSEC source: 0001415889-23-012134 · form4-08112023_040818.xml · derivative · entry 3 Cox John · CIK 0001498428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2032-05-25 F2 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F3 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $6.64 Strike: $8.28 | $4,537.78 |
DisclosureSEC source: 0001415889-23-012134 · form4-08112023_040818.xml · derivative · entry 2 Cox John · CIK 0001498428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2033-05-18 F2 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F3 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerCommon Stock | 341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-012134 · form4-08112023_040818.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share F2 · shares: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F1 · price: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right ("CVR") per share Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:20 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-23-008494 · form4-05222023_040509.xml · derivative · entry 1 Cox John · CIK 0001498428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2033-05-18 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024 Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:00 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-22-005827 · form4-05272022_050513.xml · derivative · entry 1 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 11:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $9.97 Strike: $9.97 | $88,613.36 |
DisclosureSEC source: 0001415889-21-003238 · form4-06282021_070607.xml · derivative · entry 1 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 23:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-134300 · tm2037869-2_4seq1.xml · derivative · entry 2 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. F1 · kind: Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. F2 · ownership.nature: Held by The John Gilbert Cox Living Trust dated 6/23/2006, as amended, of which the Reporting Person is the trustee. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 23:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | ConversionCommon Stock | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-134300 · tm2037869-2_4seq1.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. F2 · ownership.nature: Held by The John Gilbert Cox Living Trust dated 6/23/2006, as amended, of which the Reporting Person is the trustee. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 23:31 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,858 | $96.72 | $179,705.76 |
DisclosureSEC source: 0000899243-20-009592 · doc4.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923 Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,304 | $0.00 Strike: $42.07 | $0.00 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · derivative · entry 13 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,304 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,434 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · derivative · entry 12 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,434 shares Expires 2027-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,366 | $0.00 Strike: $26.12 | $0.00 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · derivative · entry 11 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,366 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,632 | $0.00 Strike: $41.19 | $0.00 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · derivative · entry 10 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,632 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $12.91 | $0.00 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · derivative · entry 9 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2023-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,016 | $97.17 | $98,724.72 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 8 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,781 F3 · price: $97.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.08 to $97.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,187 | $96.45 | $114,486.15 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 7 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,797 F2 · price: $96.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 24,533 | $95.13 | $2,333,824.29 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 6 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,984 F1 · price: $95.13 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 3,304 | $42.07 | $138,999.28 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 5 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 2,434 | $38.76 | $94,341.84 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 4 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 3,366 | $26.12 | $87,919.92 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 3 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 3,632 | $41.19 | $149,602.08 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 2 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 14,000 | $12.91 | $180,740.00 |
DisclosureSEC source: 0000899243-20-009121 · doc4.xml · nonDerivative · entry 1 Cox John · CIK 0001498428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.